N@N

DIAGNOS Announces the Sale of the Harricana North Property to North American Palladium Ltd

_{//health-fitness.news-articles.net/content/2009/ .. th-property-to-north-american-palladium-ltd.html}
^{Published in Health and Fitness on Thursday, November 5th 2009 at 11:06 GMT by Market Wire}  

BROSSARD, QUEBEC--(Marketwire - Nov. 5, 2009) - DIAGNOS inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in the use of artificial intelligence and advanced knowledge extraction techniques, announces today that it has signed an agreement with North American Palladium Ltd ("NAP") to sell the Harricana North Property located in Quebec's Abitibi region north-north-west of its wholly-owned Sleeping Giant mine and mill. The Harricana North Property, which offers excellent potential for gold mineralization, consists of 133 non-contiguous claims and covers a surface area of approximately 7,490 hectares.

NAP will acquire a 100% interest in the property in exchange for a payment of $20,000 and a 2% Net Smelter Return (NSR) royalty payable to DIAGNOS.

Furthermore, a $55,000 service contract has also been signed with NAP to use our CARDS (Computer Aided Resources Detection System), which NAP plans to use on its wholly-owned Sleeping Giant and Dormex properties.

Michel Fontaine, Vice-President - Business Development of DIAGNOS, stated that "We are proud to work with individuals that have shown in the past determination and perseverance. Our CARDS system will become the standard reference in order to predict high probability targets in the mining industry."

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation (TSX VENTURE:ADK), with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare, natural resources, and entertainment.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

For further information, please visit our website at [ www.diagnos.com ] or the SEDAR website at [ www.sedar.com ]. You may also contact our investor relations representative.